Wealth Enhancement Advisory Services’s Eledon Pharmaceuticals ELDN Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$133K	Buy	+34,615	New	+$126K	﹤0.01%	3729

Other funds holding ELDN

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Wealth Enhancement Advisory Services's ELDN Position: Q2 2026 in Review

Wealth Enhancement Advisory Services opened a new position in Eledon Pharmaceuticals (ELDN) in Q2 2026: 34,615 shares worth $133K. The stake represents ﹤0.01% of the portfolio and ranks #3729 among its holdings.

160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

Wealth Enhancement Advisory Services held 34,615 shares of Eledon Pharmaceuticals worth $133K as of Q2 2026.
Eledon Pharmaceuticals was a new Wealth Enhancement Advisory Services position in Q2 2026.
Eledon Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3729 holding.
160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.